SD 1388 requires nursing homes to report quarterly on the use of psychotropic medications (like antipsychotics, antidepressants, and anti-anxiety drugs) to federal agencies. Nursing homes must publicly post these reports online and document in each resident's care plan the prescriber's details, evaluation date, medical justification, and proof of informed consent. Failure to submit reports can result in fines, and repeated failures may lead to suspending new admissions. The bill directly affects nursing homes, residents receiving these medications, and prescribers by increasing transparency and accountability. It focuses on administrative reporting and documentation requirements without changing medication protocols.
This bill creates standardized "forensic units" within certain facilities to provide specialized care for specific patient populations. It defines these units as physically separate areas with incarceration-like restrictions, specialized staff training, and appropriate environments. The law mandates that individuals admitted under certain legal or medical conditions (specified in existing sections of the law) must initially be placed in these forensic units upon facility admission. The bill directly affects patients meeting those admission criteria and the facilities responsible for their care. These changes aim to establish consistent care protocols for vulnerable populations within the state's healthcare system.
By Mr. Montigny, a petition (accompanied by bill, Senate, No. 1194) of Mark C. Montigny for legislation to prevent unscrupulous medical debt recovery practices. The Judiciary.
This bill establishes five regional pilot programs across Massachusetts to test non-emergency transport options for behavioral health patients (e.g., mental health or substance use treatment), replacing ambulance use where appropriate. It requires MassHealth, insurers, and behavioral health providers to reimburse these alternative transport services for participants in the pilots. The Health Policy Commission must study the pilots’ effectiveness, measuring factors like transfer times, reduced stigma, cost-efficiency, and how reimbursement compares to traditional ambulance transport. The goal is to evaluate whether these models improve access and resource use before potentially expanding them statewide.
HD 2525 establishes a state program to advance mental health technology innovation through grants for research, development, and pilot projects. It creates a dedicated "Mental Health and Innovation Fund" (not subject to annual appropriation) to support mental healthcare technology initiatives, funded by grants, private contributions, and investment income. The bill mandates an oversight committee - including agency leaders, tech experts, and parent advocates - to guide the program and fund use. This directly affects state mental health agencies, healthcare providers receiving grants, and technology companies developing mental health solutions. The policy focuses on closing the innovation gap in mental healthcare by leveraging Massachusetts' existing strengths in biotech and medical technology sectors.
This bill defines "psychotropic" medications (including antipsychotics, antidepressants, and similar drugs) for nursing home use. It requires nursing homes to submit quarterly reports on these medications to federal health programs, publicly post the reports online, and document in resident care plans the prescriber's details, evaluation date, reasons for use, and proof of informed consent. Failure to submit reports may result in fines or suspension of new admissions. The law directly affects nursing homes, residents receiving psychotropic medications, and their guardians.
By Mr. Cyr, a petition (accompanied by bill, Senate, No. 1394) of Julian Cyr for legislation to ensure efficient and effective implementation of behavioral health reform. Mental Health, Substance Use and Recovery.
This bill (SD 937) removes an automatic expiration date for a drug stewardship program established under Chapter 52 of the 2016 Acts. It repeals Sections 55 and 77 of that law, which previously set a sunset date (ending the program on a specific future date). By eliminating this expiration, the bill ensures the drug stewardship program remains in effect indefinitely without needing future legislative action. The change directly affects the ongoing operation of the state's drug stewardship program, extending its legal authority permanently.
HD 623 requires insurance companies to cover at least 30 days of in-patient treatment for substance abuse disorders, increasing the current minimum from 14 days. The bill directly affects individuals seeking substance abuse treatment and insurance providers operating under Massachusetts law. It amends multiple sections of the state’s insurance statutes (including chapters 32A, 118E, 175, 176A, 176B, and 176G) to replace the figure "14" with "30" in coverage requirements. This is a concrete policy change to expand mandated treatment duration, without altering other insurance terms or creating new programs.
This bill (HD 2114) requires all state government agencies and boards to stock naloxone (opioid antagonist medication) and train employees annually on its use. It also directs the state department to issue nonbinding guidance encouraging private employers to do the same. The law directly affects state agencies by mandating naloxone availability and training, while private businesses receive voluntary recommendations. Key provisions focus on expanding access to life-saving medication through mandatory state action and advisory steps for private sector adoption. The bill aims to increase naloxone readiness across public and private settings without imposing new costs on businesses.
